NCT02014467 - Denosumab China Phase III Study | Biotech Hunter

Enrollment

486

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG

Denosumab

Injection

DRUG

Placebo

Injection

DIETARY_SUPPLEMENT

Elemental Calcium

Oral, at least 600 mg

DIETARY_SUPPLEMENT

Vitamin D

Oral, at least 400 IU

Trial Locations (8)

GSK Investigational Site, Beijing

GSK Investigational Site, Beijing

GSK Investigational Site, Beijing

GSK Investigational Site, Shanghai

GSK Investigational Site, Shanghai

GSK Investigational Site, Chengdu

GSK Investigational Site, Chengdu

GSK Investigational Site, Chengdu